Cagrilintide + Tirzepatide Stack Protocol - Amylin + Dual Incretin

Cagrilintide + Tirzepatide Stack Quick Reference Dosing Card

What Is the Cagrilintide + Tirzepatide Stack?

The cagrilintide + tirzepatide stack is a two-compound weight-management protocol designed to suppress appetite and improve metabolism through three separate signaling pathways — more than either compound covers alone. Cagrilintide is a long-acting amylin analogue (it mimics a natural fullness hormone), while tirzepatide is a dual GLP-1/GIP agonist (it activates two gut-hormone receptors that control appetite and blood sugar). Together, they target three receptor families: amylin/calcitonin signaling plus GLP-1 and GIP incretin signaling. This is a community-derived protocol, not an FDA-approved combination.

This stack sits between CagriSema (2-receptor with Phase 3 human data) and cagrilintide + retatrutide (4-receptor, fully speculative). The main hypothesis is that adding amylin satiety signaling to tirzepatide's stronger dual-incretin platform can outperform either monotherapy approach in selected users.

No human clinical trial has tested cagrilintide + tirzepatide directly. Protocol design is extrapolated from individual compound data, CagriSema combination logic, and preclinical combination evidence reported at ADA 2024.

Why Add Cagrilintide to Tirzepatide?

The core idea behind this stack is straightforward: tirzepatide already suppresses appetite and improves metabolism through two pathways, but it misses a third one — the amylin system. Cagrilintide fills that gap. Think of it as adding a third layer of "stop eating" signaling that works in a different part of the brain than tirzepatide reaches on its own.

Dual Incretin Foundation — What Tirzepatide Already Provides

Tirzepatide is the strongest FDA-approved single-drug option for obesity, outperforming semaglutide in comparative trials. It works by activating two receptor systems at once: GLP-1 receptors (which suppress appetite and slow digestion) and GIP receptors (which support insulin sensitivity and metabolic efficiency). Together, these two pathways are called "dual incretin" signaling. For full monotherapy data, see the full tirzepatide protocol page.

The Missing Pathway — Amylin Satiety Signaling

Tirzepatide does not activate amylin receptors — a separate system in the brainstem that controls how full you feel after eating. Cagrilintide is a long-acting amylin analogue that targets this pathway. Where tirzepatide's appetite suppression works mainly through gut hormones, cagrilintide acts on a different set of brain circuits that independently signal "you've eaten enough." Adding cagrilintide to tirzepatide means appetite suppression from two different brain regions instead of one.

Preclinical Synergy Data — ADA 2024

The only direct combination evidence comes from an animal study. Valdecantos et al. (presented at the American Diabetes Association 2024 conference) found that giving cagrilintide and tirzepatide together at lower-than-maximum doses produced greater weight reduction in obese rats than either compound alone. The combination also improved some metabolic markers. This is encouraging but limited — animal results do not always translate to humans.

Slowed Digestion From Both Sides

Both cagrilintide and tirzepatide slow how quickly food leaves your stomach, but they do it through different receptor pathways. Layering both compounds may produce stronger and longer-lasting fullness after meals. However, this overlap is also the main tolerability challenge: too much gastric slowing at once is the most common reason people struggle during the dose-escalation phase. The staggered titration protocol in the dosing section is designed to manage this.

Cagrilintide + Tirzepatide Dosing Protocol & Schedule

Format A: Separate Vials - Staggered Co-Titration

Staggered titration is recommended: establish tirzepatide tolerance first, then introduce cagrilintide and escalate both gradually.

There is no single "correct" way to run this stack. The table below shows three common approaches — ranging from a full 24-week ramp to a simpler add-on model. Your choice depends on whether you're starting fresh or already using tirzepatide, and how aggressively you want to escalate.

Protocol Notes

• Injection logistics: Both compounds are subcutaneous and typically once weekly; use different sites.
• Oral options: Neither compound is orally bioavailable in injectable form.
• Sub-maximal dosing rationale: preclinical data suggests combination benefit can appear before maximal monotherapy doses.
• Do not combine with semaglutide: tirzepatide already includes GLP-1 receptor agonism.
• Do not combine with pramlintide: cagrilintide already covers amylin agonism.

Cagrilintide + Tirzepatide Reconstitution Guide

Format A: Separate Vials

The table below shows how much bacteriostatic (BAC) water to add to each vial size and what concentration you'll get. To find your row: start with the peptide you're preparing (cagrilintide or tirzepatide), find your vial size, then look across to find your target dose — the last column tells you exactly how much liquid to draw into your syringe and how many units that equals on a standard U-100 insulin syringe.

How the math works — Tirzepatide example (10 mg vial + 1.0 mL BAC water): You get a concentration of 10 mg/mL (10,000 mcg/mL). A 5.0 mg dose = 0.50 mL = 50 units on a U-100 syringe. A 15.0 mg dose = 1.50 mL = 150 units.

How the math works — Cagrilintide example (5 mg vial + 2.0 mL BAC water): You get a concentration of 2.5 mg/mL (2,500 mcg/mL). A 2.4 mg dose = 0.96 mL = 96 units on a U-100 syringe.

7-Step Reconstitution Instructions

1. Allow vials to reach room temperature for about 10-15 minutes.
2. Disinfect stoppers with alcohol and allow to dry.
3. Draw BAC water per target concentration table.
4. Inject BAC slowly down vial wall, especially for cagrilintide.
5. Gently swirl or roll; do not shake either compound.
6. Inspect for clear, colorless solution and discard if cloudy or particulate.
7. Label each vial with compound, concentration, and date; refrigerate at 2-8 C and use within 28-30 days.

Cagrilintide + Tirzepatide Side Effects & Safety

This section covers the side effects you should be aware of before considering this stack. No human trial has tested cagrilintide and tirzepatide together, so what follows is based on each compound's individual safety data and what is known from similar combinations like CagriSema.

Stomach and digestive issues (most common concern). Both compounds independently cause nausea, vomiting, diarrhea, and constipation — especially during dose increases. Running them together is expected to make these effects more frequent and more intense during the co-escalation phase (roughly weeks 9–20 in the staggered protocol). This is the primary reason for the staggered titration schedule: it gives your body time to adjust to one compound before adding the second.

Severely slowed digestion (gastroparesis risk). Both cagrilintide and tirzepatide slow how fast food leaves your stomach, but through different pathways. Layering both may slow digestion more than either one alone. Signs to watch for include feeling full long after eating small amounts, bloating, or acid reflux that worsens after starting the second compound. This is the most important theoretical risk of this specific stack.

Injection-site reactions. Redness, swelling, or itching at the injection site is more commonly reported with cagrilintide than tirzepatide. Rotating injection sites between your abdomen, thighs, and upper arms can reduce this.

Gallbladder issues. Rapid weight loss — from any cause — can increase the risk of gallstones. This is not unique to this stack, but the combination's potential for aggressive weight loss makes it worth noting. Persistent upper-right abdominal pain after eating should be evaluated by a clinician.

Pancreas inflammation (class warning). Tirzepatide belongs to the GLP-1 drug class, which carries a standard warning about pancreatitis. Severe, persistent abdominal pain — especially pain that radiates to the back — warrants immediate medical attention.

Product quality risk. Cagrilintide is investigational and only available from research-grade suppliers. Non-pharmaceutical tirzepatide quality also varies. Using two compounds from unregulated sources increases the risk of purity or contamination issues. Third-party COA verification is especially important for multi-compound protocols.

For combined side effect considerations when stacking, see the PepPal Side Effects Guide.

Clinical Evidence Context

The table below summarizes the weight-loss evidence for each compound individually. Percentages refer to average total body weight lost from baseline — for example, "22.5% at 72 weeks" means participants lost an average of 22.5% of their starting body weight over 72 weeks of treatment.

This stack is a 3-receptor pathway model: amylin-driven satiety plus GLP-1/GIP incretin signaling. Combination evidence in humans is still absent.

Storage & Handling

Limiting factor: cagrilintide handling sensitivity (do not shake) is the stricter practical constraint even though refrigerated windows are similar.

Cagrilintide + Tirzepatide vs. CagriSema vs. Cagrilintide + Retatrutide

The table below compares this stack to the two most closely related alternatives: CagriSema (the evidence-backed combination of cagrilintide + semaglutide) and the cagrilintide + retatrutide stack (a broader but more speculative option). The key differences are how many receptor pathways each stack covers, how much human evidence exists, and complexity/cost.

Receptor abbreviation key: AMY1-3R = amylin receptors, CTR = calcitonin receptor, GLP-1R = GLP-1 receptor, GIPR = GIP receptor, GCGR = glucagon receptor.

Decision Guidance

• Choose Cagrilintide + Tirzepatide when prioritizing a pragmatic speculative model built around an FDA-approved incretin base plus amylin layering.
• Choose CagriSema when prioritizing highest combination evidence strength and lower uncertainty.
• Choose Cagrilintide + Retatrutide only for maximum receptor-coverage experimentation with higher complexity and uncertainty.

Related Stacking Protocols

CagriSema (Cagrilintide + Semaglutide)

The evidence-backed parent combination with Phase 3 data and regulatory review momentum. View CagriSema stack.

Cagrilintide + Retatrutide Stack

Higher-complexity, broader-coverage variant that adds glucagon receptor agonism. View Cagrilintide + Retatrutide stack.

Higher-Dose CagriSema (2.4/7.2 mg)

A pharmaceutical escalation path under investigation to narrow efficacy gaps with stronger incretin programs.

Frequently Asked Questions - Cagrilintide + Tirzepatide Stack

Sources & Research

1. Valdecantos P, Rada P, Ghosh S, Rondinone CM, Valverde AM. "300-OR: Beneficial Effect of the Combination Therapy of Cagrilintide, a Dual Amylin/Calcitonin Agonist, and Tirzepatide, a Dual GLP-1/GIP Agonist, on Body Weight Loss in Obese Rats." Diabetes, 2024 Link.
2. Garvey WT, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2025 Link.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022 Link.
4. Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management." The Lancet, 2021 Link.
5. Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg." The Lancet, 2021 Link.
6. Kruse T, Dahl K, Schaffer L, et al. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of Medicinal Chemistry, 2021 Link.
7. Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." The Lancet, 2023 Link.
8. Novo Nordisk "CagriSema demonstrated 23% weight loss in REDEFINE 4 vs. tirzepatide 25.5%." Press Release, 2026.
9. Dutta D, et al. "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." Indian Journal of Endocrinology and Metabolism, 2024.
10. ClinicalTrials.gov — (NCT05567796), (NCT06131437), (NCT04184622).

Related Protocols

Disclaimer